Back

Comparison of warfarin, dabigatran, rivaroxaban and apixaban for effectiveness and safety among elderly patients with atrial fibrillation: a nationwide cohort study

31 August 2020 (08:30 - 08:30)
Organised by:
Congress Presentation Part of: Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation Oral Anticoagulation ESC Premium Access ESC Congress 2020

About the speaker

Photo
Doctor Ole-Christian Walter Rutherford

Sykehuset Ostfold Kalnes, Sarpsborg (Norway)

5 More presentations in this session

Presentation thumbnail
Real-world effectiveness and the safety of anticoagulant treatment in elderly non-valvular atrial fibrillation in the ANAFIE registry, the largest real-world elderly AF registry
Doctor T. Yamashita (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Edoxaban treatment of elderly patients with atrial fibrillation in routine clinical practice: 1-year results of the non-interventional Global ETNA-AF program
Doctor T. Yamashita (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Oral anticoagulants in extremely high risk very elderly (>90 years) patients with Atrial Fibrillation
Doctor T. Chao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Clinical implications of assessment of apixaban levels in elderly atrial fibrillation patients: J-ELD AF Registry sub-cohort analysis
Doctor S. Suzuki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Bleeding risks with frailty and multimorbidity in patients with atrial fibrillation. A nationwide analysis of 1.4 million subjects
Professor L. Fauchier (Tours, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral Anticoagulant Therapy in the Elderly with Atrial Fibrillation

The Event

Event poster

ESC Congress 2020

31 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation
thumbnail
Congress Session
EHRA Myths - Device-detected atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources